Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryReplimune said it will begin a slow launch of Tudriqev, targeting 200 early adopter accounts in the first six months after approval and preparing to ship product in about 60 days. The approval gives the company an entry into the PD-1-refractory melanoma market, while leaving a confirmatory Phase 3 program still in progress.
Dr. Priya NandakumarAug 9, 2026
Medical TechnologyWhile dentistry’s preventive paradigm has long targeted cavities and periodontal disease, new thought leadership emphasizes that how teeth, muscles, and the jaw interact over a lifetime plays a foundational role in holistic oral health. As emerging science connects bite function to chronic dental problems, the industry is re-examining what truly constitutes prevention.
Dr. Priya NandakumarAug 7, 2026
Biotech InnovationReplimune’s Tudriqev immunotherapy overcame substantial regulatory hurdles and a polarized advisory committee process to become a new FDA-approved treatment for advanced melanoma. The approval comes after years of uncertainty and highlights the pivotal role of both scientific evidence and consensus-building within U.S. drug regulation.
Dr. Priya NandakumarAug 7, 2026
Biopharmaceutical IndustryShares of BioVie have halved following the release of mid-stage clinical trial data for a Parkinson’s disease treatment, raising questions in both the investor and scientific communities. The company claimed success using a different study endpoint than what had been submitted to the FDA, fueling skepticism and accelerating the broader industry debate about clinical trial rigor and biotech valuation volatility.
Dr. Priya NandakumarAug 6, 2026
Biotech InnovationThe U.S. Food and Drug Administration has granted approval to a novel narcolepsy treatment developed by Takeda, representing a significant milestone for the field. This approval is expected to benefit not only narcolepsy patients, but potentially others with related conditions, spotlighting innovations in sleep disorder therapeutics.
Dr. Priya NandakumarAug 6, 2026
Regulatory & PolicyThe announcement of the first cyclospora-related deaths in the United States underscores both the complexity of foodborne outbreaks and the critical challenges faced by public health agencies as they rush to contain and investigate the spread. This in-depth article explores the background of cyclospora, the specifics of the Michigan outbreak, and broader implications for future prevention and policy.
Dr. Priya NandakumarAug 3, 2026
Regulatory & PolicyA simmering contract dispute between Sentara Health and Anthem threatens to upend insurance coverage for hundreds of thousands of Virginians. The standoff, centered on rate renegotiations, highlights the stakes involved in payer-provider dynamics and the potential consequences for patients, providers, and the regional health ecosystem.
Dr. Priya NandakumarAug 3, 2026
Biopharmaceutical IndustryThis comprehensive analysis explores a month filled with major executive hires, departures, and notable layoffs across the biopharmaceutical sector and healthcare organizations. The evolving leadership landscape, coupled with workforce reductions at prominent companies, highlights the shifting priorities and pressures in the healthcare industry’s ongoing transformation.
Dr. Priya NandakumarAug 1, 2026
Biopharmaceutical IndustryAlnylam's recently announced revenue guidance reduction for its TTR franchise has resulted in dramatic market repercussions. Observers question the company's sales trajectory and its competitive positioning amid broader industry volatility.
Dr. Priya NandakumarJul 31, 2026
Regulatory & PolicyAmid continued public health concern, the ongoing Ebola outbreak has entered a pivotal phase, but optimism is rising as scientists indicate that a promising vaccine is close to deployment. This development could significantly influence the management of future Ebola crises and demonstrates progress in infectious disease preparedness.
Dr. Priya NandakumarJul 30, 2026
Healthcare InvestmentReverse mergers are proving a viable route for venture-backed biotechs seeking public listings. Caldera Therapeutics and Vidya Therapeutics, both with assets in immunology and inflammation, have announced go-public deals that together raised $478 million. This trend highlights the evolving dynamics and investor strategies shaping the biotech capital markets in 2026.
Dr. Priya NandakumarJul 29, 2026
Biopharmaceutical IndustryAs GSK reports substantial impairment charges for the second quarter, the UK-based pharma giant launches a sweeping cost-savings initiative designed to offset losses and safeguard future profitability. The company's new CEO seeks to balance cost reductions with investments in drugs approaching late-stage trials.
Dr. Priya NandakumarJul 28, 2026